Product
Dostarlimab-Gxly
1 clinical trial
4 indications
Indication
Endometrial Cancer Stage IIndication
Measles-Rubella Immunity DeficiencyIndication
Endometrial AdenocarcinomaIndication
Immune-related Adverse EventClinical trial
A Phase 2b, Open-label, Single Arm, Multicentre, Pilot Study of the Efficacy, Safety and Tolerability of Dostarlimab in Women With Early-stage MMR Deficient Endometrioid Endometrial Adenocarcinoma.Status: Not yet recruiting, Estimated PCD: 2026-06-30